Successful desensitization of a case with desferrioxamine hypersensitivity

Minerva Pediatrica

Volumn 58, Issue 6, 2006, Pages 571-574

  Gulen F ^a,c   Demir, E ^a   Tanac R ^a   Aydinok, Y ^a   Gulen, H ^b   Yenigun A ^a   Can, D ^a  

^a EGE UNIVERSITY   (Turkey)

^b CELAL BAYAR UNIVERSITY   (Turkey)

^c EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Allergy; Desferrioxamine; Thalassemia

Indexed keywords

CETIRIZINE; DEFEROXAMINE; DEXAMETHASONE; KETOTIFEN; PHENIRAMINE;

ALLERGIC REACTION; ARTICLE; CASE REPORT; CHELATION THERAPY; CLINICAL FEATURE; DESENSITIZATION; DOSE RESPONSE; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; HYPOTENSION; LABORATORY TEST; PRURITUS; SCHOOL CHILD; TACHYCARDIA; THALASSEMIA MAJOR; URTICARIA;

BETA-THALASSEMIA; CHILD; DEFEROXAMINE; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; SIDEROPHORES; SKIN TESTS; TIME FACTORS;

EID: 33846559354     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Will AM. Iron metabolism, sideroblastic anemia and iron overload. In: Lilleyman J, Hann I, Blanchette V editors. Pediatric Hematology. London: Churchill Livingstone; 1999.p.105-44.
2. Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E. Thalassemia. Hematology (Am Soc Hematol Educ Program) 2004;1:14-34.
3. Olivieri NF, Brittenham GM. Iron chelating therapy and the treatment of thalassemia. Blood 1997;89:739-61.
4. Propper RD, Shurin SB, Nathan DG. Reassesment of the use of desferrioksamine B in iron overload. N Engl J Med 1976;294:1421-3.
5. Pippard MJ, Callender ST, Weatherall DJ. Intensive iron-chelation therapy with desferrioxamine in iron-loading anaemias. Clin Sci Mol Med 1978;54:99-106.
6. Athanasiou A, Shepp MA, Necheles T. Anaphylactic reactions to desferrioxamine. Lancet 1977;2:616.
7. La Rosa ML, Romeo MA, Di Gregorio FD, Russo G. Desensitization treatment for anaphylactoid reactions to desferrioxamine in a pediatric patient with thalassemia. J Allergy Clin Immunology 1996;97:127-8.
8. Hofbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003;102:17-24.
9. Koren G, Bentur Y, Strong D, Harvey E, Klein J, Baumal R et al. Acute changes in renal function associated with deferoxamine therapy. Am J Dis Child 1989;143:1077-80.
10. Freedman MH, Grisaru D, Olivieri N, MacLusky I, Thorner PS. Pulmonary syndrome in patients with thalassamia receiving intravenous desferrioxamine infusions. Am J Dis Child 1990;144:565-9.
11. Daar S, Ghosh K, Nirmala V. Site of subcutaneous desferrioxamine injection is the initial site of post-transfusion urticaria in multitransfused B-thalassaemia major patients. Clin Lab Haematol 2000;22:55-8.
12. Mangiagli A, De Sanctis V, Campisi S, Di Silvestro G, Urso L. Long-term follow up and bone imaging in acquired osteochondrodysplasia in a female patient with thalassemia and desferrioxamine hypersensitivity. Minerva Pediatr 2000;52:235-41.
13. Lombardo T, Ferro G, Frontini V, Percolla S. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration. Am J Hematol 1996;51:90-2.
14. Miller KB, Rosenwasser LJ, Bessette JA, Beer DJ, Rocklin RE. Rapid desensitisation for desferrioxamine anaphylactic reactions. Lancet 1981;1:1059.
15. Bousquet J, Navarro M, Robert G, Aye P, Michel FB. Rapid desensitisation for desferrioxamine anaphylactoid reactions. Lancet 1983;2:859-60.
16. Romeo MA, Di Gregorio F, Schiliro G. Allergy to desferrioxamine. J Inherit Metab Dis 1984;7:121.
17. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003;88: 489-96.
18. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L et al. A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with {beta}-thalassemia. Blood 2006;107:3455-62.